Enanta Pharmaceuticals Inc (ENTA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Enanta Pharmaceuticals reported revenue of $65.3M, down 3.4% from $67.6M the year before. Net income was -$81.9M (a -125.4% net margin), or -$3.84 per diluted share. Gross margin was -130.7% and operating margin was -130.7%. Operating activities generated -$19.3M of cash, leaving -$32.2M of free cash flow. At fiscal year end, Enanta Pharmaceuticals held $280.7M in total assets against $216.0M in total liabilities, including $32.3M of cash and equivalents.
Open the full interactive Enanta Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Enanta Pharmaceuticals Key Stats
| Share Price | $11.52 |
|---|---|
| Market Cap | $335.1M |
| Revenue YoY Growth | -3.4% |
| 52-Week Range | $10.47 – $16.85 |
| Shares Outstanding | 29.1 million (basic, 2026 Q3) |
Enanta Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $122.5M | $97.1M | $86.2M | $79.2M | $67.6M | $65.3M |
| Cost of Goods Sold | $164.1M | $206.6M | $210.0M | $216.4M | $189.3M | $150.7M |
| Gross Profit | -$41.6M | -$109.6M | -$123.8M | -$137.2M | -$121.7M | -$85.3M |
| Operating Income | -$41.6M | -$109.6M | -$123.8M | -$137.2M | -$121.7M | -$85.3M |
| Pre-Tax Income | -$35.0M | -$107.6M | -$122.2M | -$131.0M | -$117.8M | -$83.5M |
| Income Tax | $1.1M | -$28.6M | -$433,000 | $2.8M | -$1.7M | -$1.7M |
| Net Income | -$36.2M | -$79.0M | -$121.8M | -$133.8M | -$116.0M | -$81.9M |
| Diluted EPS | -$1.81 | -$3.92 | -$5.91 | -$6.38 | -$5.48 | -$3.84 |
Enanta Pharmaceuticals Quarterly Results
| 2025 Q4 | 2026 Q1 | 2026 Q2 | 2026 Q3 | |
|---|---|---|---|---|
| Revenue | $15.1M | $18.6M | $17.2M | $14.4M |
| Net Income | -$18.7M | -$11.9M | -$13.1M | -$19.5M |
| Diluted EPS | -$0.88 | -$0.42 | -$0.45 | -$0.67 |
Enanta Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $87.1M | $57.2M | $44.0M | $85.4M | $37.2M | $32.3M |
| Current Assets | $436.8M | $319.0M | $311.7M | $422.8M | $299.9M | $204.3M |
| Total Assets | $486.1M | $438.8M | $375.4M | $462.3M | $376.7M | $280.7M |
| Current Liabilities | $24.2M | $36.2M | $29.8M | $62.8M | $57.5M | $48.6M |
| Total Liabilities | $30.6M | $39.4M | $54.1M | $245.5M | $247.8M | $216.0M |
| Shareholders' Equity | $455.6M | $399.4M | $321.3M | $216.7M | $128.8M | $64.7M |
Enanta Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $7.1M | -$70.0M | -$84.8M | -$103.2M | -$78.8M | -$19.3M |
| Cash From Investing | $19.8M | $37.0M | $54.9M | -$53.6M | $58.2M | $40.3M |
| Cash From Financing | $9.0M | $3.1M | $20.0M | $198.1M | -$27.6M | -$26.6M |
| Free Cash Flow | $5.6M | -$70.7M | -$86.9M | -$112.2M | -$96.7M | -$32.2M |
Figures from Enanta Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Enanta Pharmaceuticals financials page for every line item.
Enanta Pharmaceuticals Company Profile
| Ticker | ENTA |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Watertown, Massachusetts |
| Fiscal Year End | September 30 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001177648 |
Frequently Asked Questions
What was Enanta Pharmaceuticals' revenue in fiscal 2025?
Enanta Pharmaceuticals (ENTA) reported revenue of $65.3M for fiscal 2025.
What is Enanta Pharmaceuticals' annual revenue history?
Enanta Pharmaceuticals' annual revenue by fiscal year: 2020: $122.5M; 2021: $97.1M; 2022: $86.2M; 2023: $79.2M; 2024: $67.6M; 2025: $65.3M.
What was Enanta Pharmaceuticals' net income in fiscal 2025?
Enanta Pharmaceuticals reported net income of -$81.9M for fiscal 2025.
What was Enanta Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Enanta Pharmaceuticals' diluted EPS was -$3.84 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Enanta Pharmaceuticals generate in fiscal 2025?
Enanta Pharmaceuticals generated -$32.2M of free cash flow in fiscal 2025.
What was Enanta Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q3), Enanta Pharmaceuticals reported revenue of $14.4M.
How many shares of Enanta Pharmaceuticals are outstanding?
Enanta Pharmaceuticals reported a weighted average of 29.1 million basic shares outstanding in 2026 Q3.
What is Enanta Pharmaceuticals' market cap?
Based on its latest closing price, Enanta Pharmaceuticals (ENTA) has a market capitalization of about $335.1M.
When does Enanta Pharmaceuticals' fiscal year end?
Enanta Pharmaceuticals' fiscal year end, as registered with the SEC, is September 30.
Where is Enanta Pharmaceuticals headquartered?
Enanta Pharmaceuticals lists its business address in Watertown, Massachusetts in its SEC filings.